Tag: Cancer: Leukemia
Factors Predict Low BMD in Pediatric Blood Cancer Survivors
Low bone mineral density detected during guideline-recommended dual-energy X-ray absorptiometry
Severe Adverse Cardiovascular Events Associated With Ibrutinib
Risk up for severe, sometimes fatal, events, including supraventricular arrhythmias, CNS events
Blast Count Prognostic for CML Presenting in Advanced Phase
Mortality risk significantly higher for patients with 20 to 29 percent versus less than 20 percent blasts
Many Older Patients With AML Not Receiving Active Treatment
No active treatment more likely with older age, lower household income, unmarried status, comorbidities
Hematological Malignancy Risk Up for First-Degree Relatives
Increased familial relative risks for the same tumor type for most hematological malignancies
Medicare to Cover CAR-T Therapy for Leukemia, Lymphoma
Chimeric antigen receptor T-cell therapy boosts a patient's own immune cells
Overweight, Obesity May Up Early Mortality Risk in Pediatric ALL
But no correlation seen for overweight or obesity with early relapse in cohort of Mexican children with ALL
Ibrutinib-Rituximab Beats Chemoimmunotherapy for CLL
Progression-free, overall survival improved in the ibrutinib-rituximab group at three years
Anesthesia Tied to Neurocognitive Impairment in Childhood ALL Survivors
Survivors experience impairment with exposure to propofol, fluranes, longer anesthesia duration
High Response Seen for Chemo in Seniors With High-Risk AML
Complete response rate for patients treated with chemo was 69 percent; three-year OS was 21 percent
